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ABSTRACT  
The new substance element has been known as novel antidiabetic drug, eg: saroglitazar. saroglitazar is a medication used to treat type-2 
diabetes. saroglitazar was known under the exchange name Lipaglyn, created by Zydus cadila. lipaglyn is the first drug approved to treat type-
2diabetes mellitus by the drug controller general of India in june 2013. Lipaglyn is demonstrated for the patients experiencing diabetes 
dyslipidaemia. It is given once daily for treatment. Saroglitazar manages the lipid parameters just as glycemic control. [1] 
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INTRODUCTION:  
Dyslipidaemia is considered as one of the major risk 
factors for cardiovascular diseases (CVD) accounting for 
50% of the myocardial infarction (MI) cases worldwide.[2] 
A recent epidemiological survey on prevalence of lipid 
abnormalities of the Indian population  
by Indian Council of Medical Research-India Diabetes 
Study (ICMR-INDIAB), has shown that 79% of Indian 
subjects greater than 20 years of age have abnormalities in 
at least one of the lipid parameters.[3]In this survey, the 
commonly found lipid abnormality was low-high density 
lipoprotein cholesterol (low HDL-C) in 72% subjects 
followed by high triglycerides(TG) in 29.5% subjects and 
then high low-density lipoprotein cholesterol (LDL-C) in 
11.8% subjects.(4) Prevalence of dyslipidaemia is high in 
India, pharmacological intervention strategies are used to 
prevent and manage cardiovascular risk factor. Statins the 
first line treatment for dyslipidaemia and decrease LDL-C 
levels as well as the danger of cardiovascular occasions in 
patients with or without cardiovascular disease.[5] 
Intensive statin treatment was compared with moderate-
dose statin treatment steadily brings down LDL cholesterol 
levels and paces of non-lethal cardiovascular events.[6]The 
extent of CVD chance decrease as an outcome of LDL-C 
bringing down to the  range of 25% and 35%.[3]This 
measurably important but clinically insufficient control of 
CVD risk is to a limited extent because of a lipid treatment 
centre around LDL-C alone with a resultant disregard of 
other significant parts of lipoprotein metabolism. [7]  Statin 
treatment may not eliminate CVD Risk related with low 
HDL and high triglycerides. [8,9] This review article centres 
around raised serum triglycerides (TG) and triglyceride 
rich lipoproteins as potential components limiting further 
decrease in CVD events in spite of low on-treatment LDL-C. 
[10] 
NEWER CONCEPT —DUAL PPAR α/ℽ AGONIST: 
 Peroxisome proliferator-activated receptors (PPARs) are 
nuclear lipid-activated interpretation factors that regulates 
the expression of genes to control the lipid and lipoprotein 
metabolism, glucose homeostasis and inflammatory 
process. There are 3 PPARs subtypes which are usually 
assigned PPAR alpha, PPAR gamma and PPAR ß/d. PPAR α 
enactment builds high thickness lipoprotein cholesterol 
synthesis, stimulates "reverse" cholesterol transport and 
decreases triglycerides. PPAR activation brings about 
insulin sensitization and antidiabetic activity. Consolidated 
medicines with PPAR and an agonist may conceivably 
improve insulin resistance and ease atherogenic 
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dyslipidaemia, while PPAR d properties may prevent the 
development of overweight which ordinarily goes with 
"unadulterated" PPAR ℽ ligands. The new generation of 
double activity PPARs offer a desire for another way to 
deal with diabetes care tending to glycemia, yet 
dyslipidaemia and different segments of the metabolic 
syndrome. [11] Saroglitazar is a novel double PPAR α/ℽ 
agonist, non-thiazolidinediones (TZD) and non-fibric 
corrosive subsidiary, with an overwhelming PPAR α 
agonistic movement. It is a glitazar endorsed by Drug 
Controller General of India (DCGI) and has been found to 
have a great pre-clinical and clinical safety profile together 
with a higher adequacy in enhancing lipid and glycaemic 
targets. [12,13] 
DRUG DESCRIPTION:  
Saroglitazar (trade name Lipaglyn) is a drug to treat 
diabetes mellitus type 2 and dyslipidaemia. It is approved 
for use in India by the Drug Controller General of India. [14] 
Saroglitazar is indicated for the management of diabetic 
dyslipidaemia and hypertriglyceridemia with type 2 
diabetes mellitus which was not improved by statin 
therapy. In clinical studies, saroglitazar has shown the 
reduction in triglycerides (TG), LDL cholesterol, VLDL 
cholesterol, non-HDL cholesterol and an increase in HDL 
cholesterol a characteristic hallmark of Atherogenic 
diabetic dyslipidaemia (ADD). It has also shown favourable 
Anti-diabetic medication property by reducing the fasting 
plasma glucose and HBA1c in diabetes patients. The 
recommended dose of saroglitazar is a tablet of 4 mg once 
a day. 
CATEGORY:  
Antidyslipidemic with antidiabetic agent, Peroxisome 
Proliferator-Activated Receptor (PPAR) Alpha Agonist, 
Peroxisome Proliferator-Activated Receptor (PPAR) 
Gamma Agonist. [14] 
MECHANISM OF ACTION:  
saroglitazar is a novel first in class drug which acts as a 
dual PPAR agonist at the subtypes a (alpha) and (gamma) 
of the peroxisome proliferator-activated receptor (PPAR). 
Agonist action at PPAR alpha lowers high blood 
triglycerides, and agonist action on PPAR gamma improves 
insulin resistance and consequently lowers blood sugar. [15] 
IUPAC NAME:  
Alpha-ethoxy-4-(2-(2-methyl-5-(4-(methylithio)phenyl)-
1H-pyrrol-1-yl)ethoxy)  
  
CHEMICAL NAME: Benzene propanoic acid. 
EMPIRICA FORMULA: C25H29NO4S  
MOLECULAR MASS: 900g/mole 
COMPOSITION:  
Each uncoated tablet contains saroglitazar 4 mg, excipient 
quantity sufficient. Inactive ingredients in the tablet are 
microcrystalline cellulose, lactose, magnesium oxide, 
povidone, talc, magnesium stearate and colloidal silicon 
dioxide. [16] 
CLINICAL SAFETY / ADVERSE EVENTS WITH 
SAROGLITAZAR:   
At some stage in the medical trials, all patients on 
saroglitazar were evaluated for renal, liver, muscle, cardiac 
functions at baseline, while on therapy and at the 
completion of study. Saroglitazar become well tolerated 
over the path of medical trials and no significant changes 
were determined in these parameters. 2Decho and ECG 
findings before and after saroglitazar treatment and 
throughout the observe-up duration did no longer reveal 
any alteration in cardiac function. Edema, weight 
advantage, bone modifications, and muscle ache have been 
additionally no longer said.  
The most common adverse effects (AEs≥2) 
reported were redness, infirmity and febrility that were del
icate to moderate in nature and failed to end 
in conclusion of the drug. Saroglitazar has completed 
virtually twelve 
years of diagnosing and clinical analysis journey with 
successes while not raising any alarm of toxicity and is 
approved science Sep 2013 for clinical use in diabetic 
dyslipidaemia and hypertriglyceridemia not controlled by 
statins alone. The recommended dose of saroglitazar is 4 
mg once daily orally. the Table1 regarding this was given 
below: [17,18] 
Table 1: Clinical safety of saroglitazar 17,18] 
Phase 3RCTs Saroglitazar 
2mg (%) 
Saroglitazar 
4mg (%) 
Peripheral edema  2.4 0 
Asthma 2.4 7.3 
Gastritis 0 4.9 
Chest discomfort 2.4 2.4 
Dizziness 2.4 2.4 
Tremors 2.4 2.4 
Pain 0 - 
Pyrexia - - 
Dyspepsia - - 
 
SIDE EFFECTS:  
Major & minor side effects for Saroglitazar were: Stomach 
pain Nausea Vomiting Chest Pain Fever Dizziness. [19] 
 USES OF SAROGLITAZAR:  
Diabetic Dyslipidaemia: Saroglitazar is used to treat 
diabetic dyslipidaemia, a condition characterized by 
abnormal levels of lipids such as triglycerides and 
cholesterol in the blood of patients suffering from diabetes 
mellitus, that are not controlled by statin therapy alone. 
Hypertriglyceridemia with Type-2 Diabetes Mellitus: 
Saroglitazar is used for the treatment of hyper 
triglyceridemia, a condition characterized by elevated 
triglycerides levels in patients suffering from type 2 
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diabetes mellitus, that are not controlled by statin therapy 
alone. [19]  
EFFICACY, SAFETY AND TOLERABILITY STUDIES 
OF SAROGLITAZAR:  
Saroglitazar was planned in the year 2001 after which it 
was broadly assessed in different preclinical and clinical 
preliminaries for a long time following which it was at last 
endorsed in 2013 for showcasing in India in patients 
experiencing diabetic dyslipidaemia and 
hypertriglyceridemia in type 2 diabetic patients not 
constrained by statins alone.  
EFFICACY:  
Being a double PPAR agonist, Saroglitazar (Lipaglyn) helps 
in controlling blood glucose and Lipid parameters 
particularly high triglycerides and high non-HDL-
Cholesterol. [20] Lipaglyn successfully diminishes 
triglycerides and non-HDL-C and controls high glucose, a 
regular circumstance in Insulin Resistance condition. [21,22] 
SAFETY AND TOLERABILITY:  
Saroglitazar has not shown any of the unfavourable 
impacts like weight increase and edema that are normally 
related to comparable atoms like the glitazone class of 
drugs. [23] Because it is an insulin sensitizer, Saroglitazar 
(Lipaglyn) has less potential for hypoglycaemia. No major 
serious adrs have been accounted for; nonetheless, long 
haul cardiovascular security has not been set up. [24] 
Saroglitazar was protected and all around endured up to a 
128 MG oral portion during the single-climbing portion 
and furthermore during the investigation of the impacts of 
nourishment and sex. There was no genuine AE seen 
during the examination in any treatment arm.  
A sum of 22 AEs in 11 subjects were accounted for during 
the investigation, included rash/tingling, stomach torment, 
queasiness, hack, cold, migraine, spinal pain, body torment, 
calf torment, fever, disquietude, happiness, dyspepsia and 
looseness of the bowels; in any case, they were gentle to 
direct in force. None of the AEs was treatment new, and 
none required any treatment for goals. There was no 
clinically important pattern or change saw in clinical 
research facility, urinalysis or ECG discoveries in the fake 
treatment or treatment arms during the investigation. 
There was no reliable example or portion reliance saw in 
the AEs. [25] 
PHARMACOKINETICS:  
It is administered orally, rapidly absorbed, good oral 
bioavailability of 40%, t1/2 of about 3-4 hrs. saroglitazar 
was metabolized in to 3 minor oxidative metabolites and it 
was predominantly eliminated unchanged by the non-renal 
route (Hepatobiliary route).  
PHARMACODYNAMICS:  
PPAR an activation by saroglitazar will increase the 
internal organ (LIVER) chemical reaction (OXIDATION) of 
fatty acids (FA) and reduces the synthesis and secretion of 
Triglycerides (TG). This, in turn, will increase diversion of 
Fatty acids from peripheral tissues (Eg, Skeletal muscle 
and fat tissue) to the liver, thereby decreasing both fatty 
acid synthesis and delivery of Triglycerides to peripheral 
tissues. Saroglitazar additionally causes increased lipolysis 
and elimination of Triglyceride-rich particles from plasma 
by activating Lipoprotein Lipase (LPL) and reducing 
production of Apo C-III, an inhibitor of LPL activity. 
Saroglitazar was additionally found to reduce plasma LDL-
C. PPAR activation by saroglitazar additionally induces an 
increase in the synthesis of apolipoproteins A-I and A-II, 
and HDL-C.(27) Although saroglitazar is predominantly a 
PPAR α agonist, it additionally causes activation of PPAR ℽ 
and regulates the transcription of insulin-responsive genes 
concerned within the control of glucose production, 
transport, and utilization. Saroglitazar will increase the 
expression of diverse PPAR ℽ responsive genes concerned 
in carbohydrate and lipid metabolism, together with 
adiponectin, adipocyte fatty acid-binding protein, LPL, 
fatty acid transport protein, and fatty acid translocase 
(CD36). By increasing the expression of these genes, 
saroglitazar decreases the postprandial rise of plasma FFA, 
improves postabsorptive, insulin-mediated suppression of 
hepatic glucose output, reduces the metabolic burden on 
liver and muscle, and promotes glucose utilization. Robust 
antidiabetic drug and insulin-sensitizing effects of 
saroglitazar were observed in preclinical models, within 
which hyperglycemia and/or impaired glucose tolerance 
may be a consequence of insulin resistance in target 
tissues. [27] As mentioned, saroglitazar is preponderantly a 
PPAR α agonist, with modest PPAR ℽ agonist actions. This 
is in contrast to previously developed dual PPAR α/ℽ 
agonists, like muraglitazar, aleglitazar, and tesaglitazar, 
that had either predominantly PPAR ℽ agonistic activity or 
equivocal agonistic activity on each PPAR α and PPAR ℽ 
receptors. 
 CELL LINES AND TREATMENT:  
HepG2 cells were maintained in DMEM supplemented with 
10 percent FBS and a 100 U/mL penicillin/streptomycin 
(Invitrogen Carlsbad, CA, USA). Human hepatic stellate LX2 
cells were maintained in DMEM with five percent FBS. The 
cells were maintained at 37°C and five percent carbon 
dioxide. Palmitate (PA, Sigma- Aldrich) was conjugated to 
BSA before use in serum- starved cells. For coculture 
experiments, HepG2 and LX2 were plated on inserts (0.4- 
µm pore size, Corning, USA) and on the bottom plate at a 
ratio of 5:1 severally. the 2 different cell populations were 
cocultured for seventy-two hours and harvested for 
downstream experiments. Cells were treated with 
saroglitazar, fenofibrate, pioglitazone (all treated at 10µM 
concentration) and PA (0.75 mM) for sixteen hours. 
ribonucleic acid and protein were isolated. The relative 
gene expression of fibrosis markers was quantified by 
qPCR from the mRNA obtained from HepG2- LX2 cells 
cocultured and 18S rRNA was used as housekeeping gene. 
Isolated proteins were subjected to immunoblotting with 
antibodies specific for anti- pNFkB and total NFkB (Cell 
sign Technology; dilution 1:1000). Densitometric. For Mito 
stress assay and assessment of reactive oxygen species 
(ROS), HepG2 cells were plated at a density of 35,000 
cells/well in XFe24- well plates (Seahorse Biosciences). 
The oxygen consumption rate (OCR) was measured 
according to the manufacturers protocol. Oligomycin (2M), 
FCCP (2M), rotenone (1M) and antimycin A (1M) were 
used as inhibitors of various mitochondrial metabolic 
respiratory complexes in all wells. For the assessment of 
ROS generation, HepG2 cells were stained with 
dichlorodihydrofluorescein diacetate (DCFDA) (5 M) 
followed by washing in PBS. The harvested cells were 
suspended in PBS for detection by flow cytometry (BD 
Biosciences). For assessment of stellate cell activation, LX2 
cells were fixed in 3.7% paraformaldehyde. when PBS 
washing, cells were stained with phalloidin (1:500) and 
subsequently stained with DAPI for forty-five minutes 
followed by observation via an Olymps Fluoview Confocal 
microscopy (Tokyo, Japan). [28] 
 
Ratna Sai et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2020; 10(2):208-212 
ISSN: 2250-1177                                                                                  [211]                                                                                 CODEN (USA): JDDTAO 
POST-MARKETING SURVEILLANCE EVIDENCES OF 
EFFICACY AND SAFETY (PHASE IV STUDIES):  
An observational, multicentre, post-marketing study 
(phase IV) involving 2804 subjects by Shetty R et al [29] 
revealed that saroglitazar additionally to oral antidiabetic 
drug (at outpatient clinics) showed significant 
improvement in all lipid and glycemic parameters at three 
months follow-up. The mean baseline TG was 312.3 mg/dL 
vs. 188.7 mg/dL at three months follow-up, a major 
reduction of 35.8% (mean of % change from baseline). 
Non-HDLC levels additionally reported a major 23.4% 
mean reduction at three months follow-up. A statistically 
significant improvement in all other lipid parameters was 
also noted (a mean reduction of 16.4% in LDL-C levels, 
31.5% in VLDL-C levels, 19% in total cholesterol levels and 
mean increase of 7.3% in HDL-C levels). Analysis of 
glycaemic parameters revealed a statistically significant 
0.9% absolute reduction in glycated haemoglobin (HbA1c) 
from baseline value of 8.3% to 7.4% at three-month 
follow-up. there have been no serious adverse events or 
weight gain rumoured in study. Saroglitazar has been 
given at various International platforms, recently two 
years post-marketing surveillance data of saroglitazar was 
given at American Diabetic Association (ADA) conference, 
2016. According to the data presented in ADA 2016, two 
years use of saroglitazar in diabetic patients with high 
triglycerides showed a significant 41% reduction in TGs. 
Other lipid parameters like non-HDL-C and LDL-C also 
reduced significantly by 28% and 12% respectively. There 
was significant improvement in glycaemic parameters as 
well (HbA1c reduced by 0.7%) and it was concluded that 
two years treatment with saroglitazar is effective, safe, 
well tolerated and isn't associated with edema, weight gain 
or any other serious adverse event. [30]  
CONCLUSION: 
(31) Because of the various ethnicity of Indians, 
atherogenic dyslipidaemia is highly prevalent within the 
Indian population which comprises of high concentrations 
of TGs, low concentrations of HDL-C, and moderate 
increase in LDL-C, with an increased concentration of 
small, dense, and potentially more atherogenic particles. 
There is a growing support for unadjusted elevated 
triglyceride levels as an independent CVD risk factor and 
management of hypertriglyceridemia has currently 
become equally very important in reducing the CVD 
events. The medication out there for this current 
management of hypertriglyceridemia in T2DM have their 
own specific limitations. Therefore, within the 
management of AD, several unmet needs still exist and a 
significant residual CVD risk prevails despite the current 
optimal therapy. A dual PPAR α/ℽ agonist (saroglitazar) by 
reducing both the TG &insulin resistance with a positive 
safety profile might provide anoptimal lipid and glycaemic 
targets. Saroglitazar (a dual PPAR α/ℽ agonist) is the first 
glitazar class compound that has been approved as a 
therapeutic agent for the excellent management of 
atherogenic diabetic dyslipidaemia or 
hypertriglyceridemia in diabetes not controlled by statins 
alone. The broad range of lipid improvements associated 
with saroglitazar addresses the pattern of dyslipidaemia 
commonly seen in Indians. Additionally, by improving the 
insulin sensitivity, saroglitazar provides an optimal 
glycaemic control also. It is novel because it is the first in 
its class approved anywhere in the world, with superior 
efficacy in reducing TG and non-HDL-C and a dual action of 
controlling both dyslipidaemia and hyperglycaemia. 
However, in spite of proven therapeutic advantages, large 
outcome study of saroglitazar showing long-term 
therapeutic efficacy and safety is needed.  
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